ClinicalTrials.gg
CompletedNCT00550459INSIGHTUpdated Apr 28, 2011Results posted

Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients

A Phase 3 interventional study of Tolvaptan and Placebo in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 12 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-28.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Enrollment
10th of 20
57 · median 55
Started
2007
the only one that year
Phase 3
9 of 20
none open now
Registered
3rd of 20
by date
Lead sponsor
8 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 10th largest by enrollment, is the only one that started in 2007, is one of 9 in phase 3, and was the 3rd registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

Demonstrate an improvement in the composite scores of validated neurocognitive tests in elderly subjects with chronic sub-clinical (i.e., asymptomatic) hyponatremia.

Read the detailed description

Subjects will be randomized, with stratification by baseline sodium \<130 or ≥ 130 mEq/L[mmol/L] to receive either tolvaptan 15 mg tablet or matching placebo tablet at doses of 15, 30 or 60 mg for 21 days. During this period, fluid restrictions should be loosened or suspended, until the subject's response to therapy can be evaluated, typically over the first few days of therapy. Fluid restriction may be reinstituted at any time in subjects whose sodium fails to improve or worsens with study therapy. A forced-titration up to 60 mg of study drug by day 3 to 7 will be based on the subject's serum sodium Subjects entering the study with a serum sodium concentration less than 130 mEq/L[mmol/L] may be fluid restricted if necessary at the discretion of the Investigator. Subjects should be monitored closely during the first 24 hours of treatment for dosing titration. The total dosing duration will be up to 21 days (plus 3 day treatment window). Subjects will return to the clinic on Day 22 (+3 days) for assessments and will complete a follow-up visit on Day 28 (+2 days).

03

Conditions studied

  • Hyponatremia

Browse trials for

Keywords

  • Hyponatremia
  • Cognitive
  • Neurological Function
  • Elderly
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women and men 50 years of age or older.
  • Serum Sodium ≥123 and ≤ 134 mEq/L [mmol/L]at screening and baseline.
  • Subjects with serum sodium concentrations ≥118 and ≤122 mEq/L[mmol/L] at screening and baseline may be entered into the trial based on consultation and approval from the study medical monitor.

Exclusion criteria

Exclusion Criteria:

  • Conditions or history which may present a safety concern to the subject or their offspring or extreme susceptibility to hypotension with sudden fluid loss (aquaresis).
  • Hyponatremia that is acute, easily reversible, artifactual, or due to a condition not associated with vasopressin excess or likely to respond to aquaretic therapy.
  • Conditions associated with an independent imminent risk of morbidity and mortality.
  • Conditions which may confound the assessment of endpoints, history of poor compliance, participation in a clinical trial believed by the PI or Sponsor likely to confound endpoint assessments.
  • Conditions which may confound primary endpoints of cognitive function.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
57 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo tablet given once a day for 21 days

    Drug: Placebo

  • Active comparator
    2

    Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.

    Drug: Tolvaptan

Interventions

  • 15-60 mg oral tablet given once a day for 21 days.

    Also known as: OPC-41061

  • DrugPlacebo

    Placebo tablet given once daily for 21 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)

    Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize "yes" 50 times;Choice=recognize "yes" or "no" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data

    Time frame: baseline and Day 22

Secondary outcomes

  1. Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests

    Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population

    Time frame: baseline and Day 22

  2. Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test

    Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population

    Time frame: baseline and Day 22

  3. Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test

    Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population

    Time frame: baseline and Day 22

  4. Change From Baseline in Overall Neurocognitive Composite Score

    Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population

    Time frame: baseline and Day 22

  5. Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)

    Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population

    Time frame: baseline and Day 22

  6. Change From Baseline in Postural Stability Test

    Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population

    Time frame: baseline and Day 22

  7. Change From Baseline in Serum Sodium; ITT Population

    Change from Baseline to Day 22 in Serum Sodium; ITT population

    Time frame: Baseline and Day 22

  8. Number of Patients With Vital Sign Abnormalities: Blood Pressure

    Incidence of abnormal systolic \& diastolic blood pressure values post-baseline (abnormal systolic values: \>=180 mmHg + increase of \>=20 mmHg, \<= 90 mmHg + decrease \>=20 mmHg; abnormal diastolic values: \>=105 mmHg+increase of \>=15 mmHg, \<=50 mmHg + decrease of \>= 15 mmHg)

    Time frame: 28 days

  9. Number of Patients With Vital Sign Abnormalities: Pulse Rate

    Incidence of abnormal pulse rate post-baseline \[abnormal values: \>=120 beats per minute (bpm) + increase of \>=15 bpm; \<=50 bpm + decrease of \>=15 bpm\]

    Time frame: 28 days

  10. Number of Patients With Vital Sign Abnormalities: Body Weight

    Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \>=7%)

    Time frame: 28 days

  11. Number of Patients With Vital Sign Abnormalities: Body Temperature

    Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \>=1.1 to \>=38.3 degrees Celsius)

    Time frame: 28 days

  12. Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin

    Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)

    Time frame: 28 days

  13. Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)

    Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)

    Time frame: 28 days

  14. Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes

    Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)

    Time frame: 28 days

  15. Number of Patients With Hematology Laboratory Abnormalities: Neutrophils

    Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)

    Time frame: 28 days

  16. Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)

    Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)

    Time frame: 28 days

  17. Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid

    Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)

    Time frame: 28 days

  18. Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol

    Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)

    Time frame: 28 days

  19. Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose

    Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)

    Time frame: 28 days

  20. Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium

    Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)

    Time frame: 28 days

  21. Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)

    Incidence of potentially clinically significant ECG abnormalities (QT\>500 msec) post-baseline

    Time frame: 28 days

  22. Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval

    Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \> 100 msec)

    Time frame: 28 days

  23. Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec

    Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)

    Time frame: 28 days

  24. Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec

    Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)

    Time frame: 28 days

  25. Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment

    Incidence of potentially clinically significant ECG abnormalities: ST Segment

    Time frame: 28 days

  26. Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave

    Incidence of potentially clinically significant ECG abnormalities: T wave

    Time frame: 28 days

  27. Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)

    Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)

    Time frame: 28 days

  28. Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia

    Incidence of potentially clinically significant ECG abnormalities: arrhythmia

    Time frame: 28 days

07

Results

Posted Apr 28, 2011
Limitations and caveats
Pilot study powered only for serum Na+ improvements. Trial lacked sufficient power to detect changes in neurocognitive test scores and SF-12 and HDS outcomes.

Participant flow

16 United States (US) sites/clinics; first subject signed informed consent on 9/11/07; last subject's final visit on 12/16/08

Participant flow — Overall Study
MilestonePlaceboTolvaptan (15-60 mg)
Started2829
Completed2726
Not completed13
Withdrew: Adverse event02
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryChange From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)

Change from baseline to Day 22 in sum of all speed domain Z-scores:Reaction Time (Simple=recognize "yes" 50 times;Choice=recognize "yes" or "no" 50 times;Digit Vigilance=match 45 digits);Psychomotor Speed (Morse Tapping=tap button for 30 seconds with right \& left hands);Processing Speed (Rapid Visual Information Processing=detect consecutive sequences of 3 odd or 3 even digits;Numeric Working Memory=recognize numbers from series of 5 digits among 30;Word Recognition=remember 15 prior learned words from 30 total;results age-matched to healthy controls from Cognitive Drug Research normative data

Time frame:
baseline and Day 22
Reported as:
Mean · Z-score
Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)
Z-scorePlaceboTolvaptan (15-60 mg)
Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)0.20 ± 0.610.39 ± 0.49
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = 0.08 (Secondary endpoints were ordered in 5 tiers to be analyzed only when \>=1 of the endpoints in the prior tier were significant. Since primary endpoint not stat significant, analyses of secondary endpoint tiers presented for exploratory purposes only) · Mean difference (net): 0.23 · 95% CI -0.03 to 0.50ANCOVA with factors of treatment, disease severity, age(6 Degrees of Freedom), and covariate baseline to fit primary endpoint using the ITT dataset.
SecondaryChange From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests

Change from baseline in the individual neurocognitive domains Z-score for Reaction Time in Computer Tests (simple reaction time test, choice reaction time test, digit vigilance test); ITT population

Time frame:
baseline and Day 22
Reported as:
Mean · Z-score
Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests
Z-scorePlaceboTolvaptan (15-60 mg)
Change From Baseline to Day 22 in the Individual Neurocognitive Domains Included in the Primary Endpoint: Reaction Time in Computer Tests0.21 ± 0.860.33 ± 0.41
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = 0.21 (ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.) · Mean difference (net): 0.20 · 95% CI -0.12 to 0.51
SecondaryChange From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test

Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Psychomotor Speed (mean tap rate of Morse tapping test); ITT population

Time frame:
baseline and Day 22
Reported as:
Mean · Z-score
Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test
Z-scorePlaceboTolvaptan (15-60 mg)
Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Psychomotor Speed Via Morse Tapping Test0.04 ± 0.360.31 ± 0.46
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = 0.02 (ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.) · Median difference (net): 0.27 · 95% CI 0.04 to 0.51
SecondaryChange From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test

Change from baseline to Day 22 in the individual neurocognitive domains Z-score for Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test; ITT population

Time frame:
baseline and Day 22
Reported as:
Mean · Z-score
Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test
Z-scorePlaceboTolvaptan (15-60 mg)
Change From Baseline in the Individual Neurocognitive Domains Included in the Primary Endpoint: Processing Speed of Rapid Visual Information Processing Test, Numeric Working Memory Test, and Word Recognition Test0.24 ± 0.750.48 ± 0.91
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = 0.21 (ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.) · Mean difference (net): 0.26 · 95% CI -0.15 to 0.67
SecondaryChange From Baseline in Overall Neurocognitive Composite Score

Change from Baseline to Day 22 in the overall Neurocognitive Composite Score (NCS)comprising the sum of 7 neurocognitive domain Z-scores (Reaction Time, Psychomotor Speed, Processing Speed, Continuity of Attention, Working Memory/Executive Functions, Quality of Episodic Verbal Memory, and Postural Stability); ITT population

Time frame:
baseline and Day 22
Reported as:
Mean · Z-score
Change From Baseline in Overall Neurocognitive Composite Score
Z-scorePlaceboTolvaptan (15-60 mg)
Change From Baseline in Overall Neurocognitive Composite Score0.19 ± 0.390.30 ± 0.39
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = 0.16 (ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.) · Mean difference (net): 0.12 · 95% CI -0.05 to 0.30
SecondaryChange From Baseline in Gait Test (Timed Get-Up-and-Go Test)

Change from baseline to Day 22 in Gait Test (Timed Get-Up-and-Go Test=time it takes for a seated subject to rise from a chair, walk 3 meters, walk around an object and return to sit in chair. Values: under 10 sec (no difficulties), 10 to 20 sec (starting to have balance difficulty), over 30 sec (at high risk for falls and dependent in most activities of daily living and mobility); test assesses risk to elderly subjects of falling and higher scores in seconds indicate higher risk of falling; ITT population

Time frame:
baseline and Day 22
Reported as:
Mean · Seconds
Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)
SecondsPlaceboTolvaptan (15-60 mg)
Change From Baseline in Gait Test (Timed Get-Up-and-Go Test)1.06 ± 5.63-0.43 ± 1.54
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = 0.23 (ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.) · Median difference (final values): -1.51 · 95% CI -4.02 to 1.00
SecondaryChange From Baseline in Postural Stability Test

Change from baseline to Day 22 in Postural Stability Test Z-score (This test measures gross motor control. The ability to stand upright without moving is assessed using the SWAY meter that is modeled on the Wright Ataxiameter. A cord from the meter is attached to the subject who is required to stand as still as possible with feet apart and eyes closed for 1 minute. The test is then repeated with eyes open for 1 minute. The outcomes of these tests are combined and measured as a movement Z-score. Higher result=better postural stability); ITT population

Time frame:
baseline and Day 22
Reported as:
Mean · Z-score
Change From Baseline in Postural Stability Test
Z-scorePlaceboTolvaptan (15-60 mg)
Change From Baseline in Postural Stability Test1.3 ± 4.68-0.35 ± 2.33
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = 0.18 (ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.) · Mean difference (net): -0.83 · 95% CI -2.04 to 0.38
SecondaryChange From Baseline in Serum Sodium; ITT Population

Change from Baseline to Day 22 in Serum Sodium; ITT population

Time frame:
Baseline and Day 22
Reported as:
Mean · mEq/L
Change From Baseline in Serum Sodium; ITT Population
mEq/LPlaceboTolvaptan (15-60 mg)
Change From Baseline in Serum Sodium; ITT Population2.23 ± 3.517.04 ± 3.39
Statistical analysis
  • Placebo vs Tolvaptan (15-60 mg) · ANCOVA · p = <0.0001 (ANCOVA with factors of treatment, disease severity, age, and severity by age interaction, and baseline as covariate. The estimated treatment and its 95% CI were provided under the model along with the p-value.) · Mean difference (net): 4.75 · 95% CI 2.89 to 6.60
SecondaryNumber of Patients With Vital Sign Abnormalities: Blood Pressure

Incidence of abnormal systolic \& diastolic blood pressure values post-baseline (abnormal systolic values: \>=180 mmHg + increase of \>=20 mmHg, \<= 90 mmHg + decrease \>=20 mmHg; abnormal diastolic values: \>=105 mmHg+increase of \>=15 mmHg, \<=50 mmHg + decrease of \>= 15 mmHg)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Vital Sign Abnormalities: Blood Pressure
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Vital Sign Abnormalities: Blood Pressure20
SecondaryNumber of Patients With Vital Sign Abnormalities: Pulse Rate

Incidence of abnormal pulse rate post-baseline \[abnormal values: \>=120 beats per minute (bpm) + increase of \>=15 bpm; \<=50 bpm + decrease of \>=15 bpm\]

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Vital Sign Abnormalities: Pulse Rate
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Vital Sign Abnormalities: Pulse Rate00
SecondaryNumber of Patients With Vital Sign Abnormalities: Body Weight

Incidence of clinically significant body weight change post-baseline (defined as change upward or downward of \>=7%)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Vital Sign Abnormalities: Body Weight
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Vital Sign Abnormalities: Body Weight11
SecondaryNumber of Patients With Vital Sign Abnormalities: Body Temperature

Incidence of potentially clinically significant changes in body temperature post-baseline (defined as an increase of \>=1.1 to \>=38.3 degrees Celsius)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Vital Sign Abnormalities: Body Temperature
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Vital Sign Abnormalities: Body Temperature10
SecondaryNumber of Patients With Hematology Laboratory Abnormalities: Hemoglobin

Incidence of clinically significant hemoglobin abnormalities post-baseline (normal range=11.8-16.8 g/dL)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Hematology Laboratory Abnormalities: Hemoglobin01
SecondaryNumber of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)

Incidence of potentially clinically significant Activated Partial Thromboplastin Time (aPTT) levels post-baseline (normal range=22-34 seconds)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Hematology Laboratory Abnormalities: Activated Partial Thromboplastin Time (aPTT)13
SecondaryNumber of Patients With Hematology Laboratory Abnormalities: Lymphocytes

Incidence of potentially clinically significant lymphocyte count post-baseline (normal range = 16-46%)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Hematology Laboratory Abnormalities: Lymphocytes12
SecondaryNumber of Patients With Hematology Laboratory Abnormalities: Neutrophils

Incidence of potentially clinically significant neutrophil count post-baseline (normal range=1.8-8 thousands/microliter)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Hematology Laboratory Abnormalities: Neutrophils
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Hematology Laboratory Abnormalities: Neutrophils20
SecondaryNumber of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)

Incidence of potentially clinically significant BUN levels post-baseline (normal range=7-30 mg/dL)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Serum Chemistry Laboratory Abnormalities: Blood Urea Nitrogen (BUN)12
SecondaryNumber of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid

Incidence of potentially clinically significant uric acid levels post-baseline (normal range=4-8.5 mg/dL)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Serum Chemistry Laboratory Abnormalities: Uric Acid01
SecondaryNumber of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol

Incidence of potentially clinically significant cholesterol levels post-baseline (normal range=0-199 mg/dL)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Serum Chemistry Laboratory Abnormalities: Cholesterol02
SecondaryNumber of Patients With Serum Chemistry Laboratory Abnormalities: Glucose

Incidence of potentially clinically significant glucose levels post-baseline (normal range=70-125 mg/dL)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Serum Chemistry Laboratory Abnormalities: Glucose20
SecondaryNumber of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium

Incidence of potentially clinically significant magnesium levels post-baseline (normal range=1.2-2 mEq/L)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Serum Chemistry Laboratory Abnormalities: Magnesium01
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)

Incidence of potentially clinically significant ECG abnormalities (QT\>500 msec) post-baseline

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: QT >500 Milliseconds (Msec)10
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval

Incidence of potentially clinically significant ECG abnormalities involving QRS interval (change \> 100 msec)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: QRS Interval11
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec

Incidence of potentially clinically significant ECG abnormalities (QTcB increase 30-60 msec)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcB Increase 30-60 Msec34
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec

Incidence of potentially clinically significant ECG abnormalities (QTcF increase 30-60 msec post-baseline)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: QTcF Increase 30-60 Msec23
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment

Incidence of potentially clinically significant ECG abnormalities: ST Segment

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: ST Segment02
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: T Wave

Incidence of potentially clinically significant ECG abnormalities: T wave

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: T Wave11
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)

Incidence of potentially clinically significant ECG abnormalities: Right bundle branch block (RBBB), Left bundle branch block (LBBB), myocardial infarction (MI)

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: Right Bundle Branch Block (RBBB), Left Bundle Branch Block (LBBB), Myocardial Infarction (MI)01
SecondaryNumber of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia

Incidence of potentially clinically significant ECG abnormalities: arrhythmia

Time frame:
28 days
Reported as:
Number · participants
Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia
participantsPlaceboTolvaptan (15-60 mg)
Number of Patients With Electrocardiogram (ECG) Abnormalities: Arrhythmia26

Adverse events

Collected over 28 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/28 (3.6%)13/28 (46.4%)
Tolvaptan (15-60 mg)—2/29 (6.9%)17/29 (58.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboTolvaptan (15-60 mg)
BradycardiaCardiac disorders1/280/29
Abdominal adhesionsGastrointestinal disorders0/281/29
Abdominal distensionGastrointestinal disorders0/281/29
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/281/29
ConstipationGastrointestinal disorders0/281/29
Large intestinal obstructionGastrointestinal disorders0/281/29
NauseaGastrointestinal disorders0/281/29
VomitingGastrointestinal disorders0/281/29
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboTolvaptan (15-60 mg)
ThirstGeneral disorders2/286/29
PollakiuriaRenal and urinary disorders3/284/29
Weight decreasedInvestigations0/284/29
Oedema peripheralGeneral disorders3/282/29
Urine output increasedInvestigations0/283/29
DermatitisSkin and subcutaneous tissue disorders2/280/29
DizzinessNervous system disorders2/282/29
FatigueGeneral disorders2/282/29
Dry MouthGastrointestinal disorders0/282/29
NasopharyngitisInfections and infestations1/282/29

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboTolvaptan (15-60 mg)Total
<=18 years000
Between 18 and 65 years6612
>=65 years222345
Age Continuous
Age Continuous(years)PlaceboTolvaptan (15-60 mg)Total
Mean71.3 ± 9.771.1 ± 10.271.2 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTolvaptan (15-60 mg)Total
Female191534
Male91423
Region of Enrollment
Region of Enrollment(participants)PlaceboTolvaptan (15-60 mg)Total
United States282957
08

Study locations

12 sites
  • Sarah. S. Olelewe, MD
    Hawthorne, California 90250, United States
  • Progressive Clinical Research
    Vista, California 92083, United States
  • Pikes Peak Cardiology
    Colorado Springs, Colorado 80907, United States
  • Innovative Research of West FL
    Largo, Florida 33770, United States
  • Coastal Nephrology Assoc. Research Center
    Punta Gorda, Florida 33950, United States
  • Rockdale Medical Research Associates
    Conyers, Georgia 30094, United States
  • Otis Barnum, DO
    Natchitoches, Louisiana 71457, United States
  • Lillestol Research, LLC
    Fargo, North Dakota 58106, United States
  • Carolina Research Associates
    Columbia, South Carolina 29201, United States
  • Wayne O. Wells, MD
    Lebanon, Tennessee 37087, United States
  • Memorial Clinical Associates
    Houston, Texas 77043, United States
  • Mitchell Rosner, MD
    Charlottesville, Virginia 22908, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 2 months after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2007
First posted
Oct 29, 2007
Start
Aug 2007
Primary completionActual
Feb 2009
CompletionActual
Mar 2009
Results delay requested
Feb 24, 2010
Results first posted
Apr 28, 2011
Last update
Apr 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00550459
First posted
Oct 29, 2007
Start date
Aug 2007
Primary completion
Feb 2009
Completion
Mar 2009
Results posted
Apr 28, 2011
Last update
Apr 28, 2011

Study contacts

Joseph Verbalis, MD
principal investigator · Georgetown University, Washington, DC, 20007 USA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion